0RGI.L - Cosmo Pharmaceuticals N.V.
| Previous close | 47.59 |
| Open | 47.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 47.25 - 47.45 |
| 52-week range | 42.60 - 69.40 |
| Volume | |
| Avg. volume | 1,466 |
| Market cap | 6.961M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | 0.36 |
| EPS (TTM) | 1.30 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting
Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGMCosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting 26.05.2023 / 16:30 GMT/BSTDublin, Ireland – 26 May 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders.A total of 7,512,823 ordinary shares in the share capital of Cosmo were represented at this annual general meeting of shareholders co
Simply Wall St.Cosmo Pharmaceuticals N.V. (VTX:COPN) Is About To Go Ex-Dividend, And It Pays A 2.0% Yield
Readers hoping to buy Cosmo Pharmaceuticals N.V. ( VTX:COPN ) for its dividend will need to make their move shortly, as...
- Simply Wall St.
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With its stock down 17% over the past three months, it is easy to disregard Cosmo Pharmaceuticals (VTX:COPN). However...
- Simply Wall St.
Cosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 58% loss from investing in the stock five years ago
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...
- EQS Group
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
Cosmo Pharmaceuticals N.V. / Key word(s): AgreementCosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings 30.03.2023 / 06:00 GMT/BSTDublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansion of the license agreement for Lumeblue™ with China Medical System Holdings Limited (“CMS”) (SEHK: 867). The expansion goes beyond the existing licensed territories (Greater
- Simply Wall St.
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/E Still Appears To Be Reasonable
With a price-to-earnings (or "P/E") ratio of 53.2x Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be sending very bearish...
ZacksMedtronic (MDT) to Enhance AI Innovation With New Platform
Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
- EQS Group
Cosmo reports record 2022 financial results exceeding guidance,increased dividend by 10%, confirms 2023 guidance
Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results23-March-2023 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 23 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022. Financial highlights In 2022, Cosmo has overtaken the €100 million annual
- EQS Group
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement22-March-2023 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 22 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its fully owned subsidiary Cosmo Intelligent Medical Devices – IMD is expanding its cooperation with Medtronic, the world’s largest healt
- EQS Group
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
Cosmo Pharmaceuticals N.V. / Key word(s): Annual ResultsInvitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023 16.03.2023 / 06:00 GMT/BSTDublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its full-year 2022 results on Thursday, 23 March 2023 at 07:00 am CET. Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast
- EQS Group
Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Cosmo Pharmaceuticals N.V. / Key word(s): Preliminary Results16-Feb-2023 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 16 February 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2022. Total revenues of €102.1m vs. guidance of €90m - €100m, representing
- Simply Wall St.
Private companies account for 46% of Cosmo Pharmaceuticals N.V.'s (VTX:COPN) ownership, while individual investors account for 36%
If you want to know who really controls Cosmo Pharmaceuticals N.V. ( VTX:COPN ), then you'll have to look at the makeup...
- EQS Group
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement21-Dec-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clasco
- EQS Group
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
Cosmo Pharmaceuticals N.V. / Key word(s): Study resultsCosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK). In the trial, Lumeblue™ was compared to placebo in white light colonoscopy with the purpo
- Simply Wall St.
Is Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Cosmo Pharmaceuticals' (VTX:COPN) stock increased significantly by 20% over...
- Simply Wall St.
Cosmo Pharmaceuticals (VTX:COPN) adds €69m to market cap in the past 7 days, though investors from five years ago are still down 60%
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) shareholders should be happy to see the share price up 20% in the last month...
- EQS Group
Cosmo announces FDA grants orphan-drug designation ofrifamycin for treatment of pouchitis
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory ApprovalCosmo announces FDA grants orphan-drug designation ofrifamycin for treatment of pouchitis 20.10.2022 / 06:00 GMT/BSTDublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orphan-drug designation request of rifamycin for treatment of pouchitis.Patients with ulcerative colitis (UC) may require removal of their colon and rectum (proctocolectomy), and the surgi
- EQS Group
GI Genius™ named to FORTUNE 2022 “Change the World” list
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousGI Genius™ named to FORTUNE 2022 “Change the World” list 12.10.2022 / 06:00 GMT/BSTDublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release that GI Genius™ intelligent endoscopy module has been named to the prestigious FORTUNE 2022 “Change the World” list.Today, the GI Genius™ module is the first commercially av
- EQS Group
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousMedtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening 06.10.2022 / 06:15 GMT/BSTDublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release that it has been awarded a contract for its Gastrointe
- EQS Group
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement04-Oct-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, It
- EQS Group
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results28-Jul-2022 / 06:06 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million
- EQS Group
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement28-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Ko
- EQS Group
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement26-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea, a subsidiary
- EQS Group
Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022
Cosmo Pharmaceuticals N.V. / Key word(s): ConferenceInvitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022 06.07.2022 / 06:00 Dublin, Ireland – 6 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2022 results on Thursday, 28 July 2022 at 07:00 am CEST. Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast which will follow at 2:00 pm CEST with Alessandro Dell
- EQS Group
Cosmo announces acceptance of NDA submission of Cortiment® MMX® in Japan
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous28-Jun-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Dublin, Ireland – 28 June 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices